Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Testimony of John F. Crowley President and CEO,…
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
All Letters, Testimony & Comments
  • Show All
Search
Results
September 21, 2022
On behalf of the broad and diverse stakeholders in American Agriculture we represent, we urge you to work with your colleagues to expeditiously confirm Doug  McKalip as Chief Agricultural Negotiator at the Office of the U.S. Trade…
September 13, 2022
On Tuesday, September 13th, BIO submitted comments in response to the FDA’s recent draft guidance on voluntary consensus standards (VCS) for regenerative medicine therapies. In the comment letter, BIO expressed appreciation to FDA for issuing a…
September 9, 2022
Today, BIO submitted comments to the World Health Organization (WHO) regarding its revised, draft white paper on the regulation of Cell and Gene Therapy Products (CGTPs). As stated previously, BIO emphasized that this paper represents a major…
September 8, 2022
As the federal government begins to implement IRA, BIO urges the administration to take additional steps to foster the development and deployment of pioneering technologies that will further reduce greenhouse gas emissions in manufacturing,…
August 31, 2022
Today, BIO submitted comments in response to the FDA’s recent draft guidance on the development, maintenance, and implementation of Risk Management Plans (RMPs). While the comment letter expressed broad support for the systematic approach for…
August 2, 2022
On behalf of the Biotechnology Innovation Organization, I want to thank you for introducing the Patent Eligibility Restoration Act. This important legislation will bring much-needed and overdue clarity to Section 101 of the Patent Act. The existing…
July 29, 2022
The Council of State Bioscience Associations (CSBA) is an alliance of independent, state and territory based, non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
July 15, 2022
BIO submitted a statement for the record to the U.S. House of Representatives Select Committee on the Climate Crisis for the committee's hearing titled "Climate Smart From Farm to Fork: Building an Affordable and Resilient Food Supply Chain." BIO's…
July 7, 2022
A coalition of 96 food and agriculture organizations signed a letter supporting the nomination of Doug McKalip as the Chief Agricultural Negotiator at the Office of the U.S. Trade Representative. The letter to Senate Finance Committee leadership…